Literature DB >> 17120728

Vaccination with a recombinant chicken FGFR-1 bypasses immunological tolerance against self-FGFR-1 in mice.

Shaojiang Zheng1, Fengying Huang, Shaoping Zheng, Wei Wang, Hui Yin, Renliang Wu.   

Abstract

The possibility that a recombinant protein vaccine based on xenogeneic homologous FGFR-1 of chicken induces production of autoantibodies against self-FGFR-1 in BALB/c mice was examined by using ELISA, Western blot analysis and ELISPOT assay respectively. Autoantibodies against mouse FGFR-1 were identified by Western blot analysis and ELISA. Compared with the two control groups, the number of APBCs, which were detected by ELISPOT assay, was significantly increased in the spleens of mice immunized with cFR1 (P < 0.05). IgG1 and IgG2b, which were detected by ELISA, were the major subclasses and were substantially increased in response to chicken FGFR-1 when compared with control group. The recombinant chicken FGFR-1 protein used as a vaccine can induce autoantibodies against self-FGFR-1 in mice and provide a basis for the active immunotherapy of tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120728     DOI: 10.1007/s11596-006-0401-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  15 in total

1.  Angiogenesis research. Cancer drugs found to work in new way.

Authors:  M Barinaga
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

Review 2.  Angiogenesis-dependent diseases.

Authors:  J Folkman
Journal:  Semin Oncol       Date:  2001-12       Impact factor: 4.929

3.  The Drosophila genome sequence: implications for biology and medicine.

Authors:  T B Kornberg; M A Krasnow
Journal:  Science       Date:  2000-03-24       Impact factor: 47.728

4.  A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.

Authors:  C C Czerkinsky; L A Nilsson; H Nygren; O Ouchterlony; A Tarkowski
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

5.  Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination.

Authors:  Polly D Gregor; Jedd D Wolchok; Vandana Turaga; Jean-Baptiste Latouche; Michel Sadelain; Dean Bacich; Warren D W Heston; Alan N Houghton; Howard I Scher
Journal:  Int J Cancer       Date:  2005-09-01       Impact factor: 7.396

6.  Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development.

Authors:  S M Plum; J W Holaday; A Ruiz; J W Madsen; W E Fogler; A H Fortier
Journal:  Vaccine       Date:  2000-12-08       Impact factor: 3.641

7.  Aberrant expression of fibroblast growth factor receptor-1 in prostate epithelial cells allows induction of promatrilysin expression by fibroblast growth factors.

Authors:  T S Udayakumar; R D Klein; M S Maliner; R B Nagle; G T Bowden
Journal:  Int J Cancer       Date:  2001-01-15       Impact factor: 7.396

8.  Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis.

Authors:  Marianne Valesky; Aaron J Spang; Gregory W Fisher; Daniel L Farkas; Dorothea Becker
Journal:  Mol Med       Date:  2002-02       Impact factor: 6.354

9.  CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.

Authors:  Polly D Gregor; Jedd D Wolchok; Cristina R Ferrone; Heidi Buchinshky; Jose A Guevara-Patiño; Miguel-Angel Perales; Fariborz Mortazavi; Dean Bacich; Warren Heston; Jean-Baptiste Latouche; Michel Sadelain; James P Allison; Howard I Scher; Alan N Houghton
Journal:  Vaccine       Date:  2004-04-16       Impact factor: 3.641

10.  Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines.

Authors:  Roopa Srinivasan; Jedd D Wolchok
Journal:  J Transl Med       Date:  2004-04-16       Impact factor: 5.531

View more
  2 in total

1.  Anti-angiogeneic target therapy for cancer with vaccine based on the recombinant chicken FGFR-1 in tumor-bearing mice.

Authors:  Shaoping Zheng; Junzhi Zhang; Shaojiang Zheng; Fengying Huang; Renliang Wu; Limin Cao; Mingxing Xie
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-04

2.  Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.

Authors:  Shao-Jiang Zheng; Shao-Ping Zheng; Feng-Ying Huang; Chang-Liang Jiao; Ren-Liang Wu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.